酒精性肝炎的肝移植治疗
肝移植已成为危及生命的酒精相关肝硬化的标准治疗,但作为重度酒精性肝炎的治疗选择仍存禁忌。欧洲先导研究及美国回顾性分析的成功,使对内科治疗无反应的高度筛选重度酒精性肝炎患者肝移植成为范式转变。仍需前瞻性研究解决筛选标准与长期酒精使用障碍结局的争议。
要点
- 肝移植是危及生命的酒精相关肝硬化的标准治疗。
- 许多中心采用6个月戒酒要求,使酒精性肝炎成为肝移植禁忌。
- 欧洲先导研究及美国回顾性分析支持对内科治疗无反应的重度酒精性肝炎患者行肝移植。
核心结论
- 欧洲先导研究及美国回顾性分析的成功,代表对内科治疗无反应的高度筛选重度酒精性肝炎患者肝移植治疗的范式转变。
- 仍需前瞻性研究解决围绕酒精性肝炎患者肝移植筛选标准及长期酒精使用障碍结局的争议。
研究设计与样本
- 综述性文章,总结肝移植作为重度酒精性肝炎治疗的证据,包括一项欧洲先导研究及美国回顾性分析。
主要发现
- 许多中心采用6个月戒酒要求(所谓「6个月规则」),使酒精性肝炎成为肝移植禁忌。
- 欧洲先导研究及美国回顾性分析显示,对内科治疗无反应的高度筛选重度酒精性肝炎患者肝移植成功。
局限性
- 仍需前瞻性研究解决围绕酒精性肝炎患者肝移植筛选标准及长期酒精使用障碍结局的争议。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
While liver transplantation (LT) has become a standard therapy for life-threatening alcohol related cirrhosis, LT as a treatment for severe alcoholic hepatitis (AH) has remained a taboo owing to concerns about the limited organ supply and the risk that the AH liver recipient will return to harmful drinking. The adoption of a 6-month abstinence requirement (the so-called '6-month rule') by many centres made AH a contraindication to LT. Given the high short-term mortality of severe AH, the lack of effective medical therapies and an increasing recognition that the 6-month rule unfairly excluded otherwise favourable candidates, a seminal European pilot study of LT for AH was performed. The success of the European study, which has been corroborated in retrospective analyses from the United States, represented a paradigm shift in therapy for highly selected patients with severe AH who are not responding to medical therapy. However, prospective studies are urgently needed to resolve the controversies that still surround the criteria for selection of patients with AH for LT and the long-term outcomes of the associated alcohol use disorder.
引用
- Im GY, Cameron AM, Lucey MR, et al. Liver transplantation for alcoholic hepatitis. J Hepatol. 2019. PMID: 30658734. doi:10.1016/j.jhep.2018.11.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。